SCHEMBL7928834

SCHEMBL7928834

COc1ccc(-c2ccc3cc(C(=O)O)ccc3c2)cc1C1(C)CCCCC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARB P10826 15/20 1.00
RARG P13631 15/20 1.00
RARA P10276 14/20 1.00
MEN1 O00255 2/20 0.64
KMT2A Q03164 2/20 0.64
LMNA P02545 2/20 0.64
NR1I2 O75469 1/20 0.64
PGR P06401 1/20 0.64
HSPD1 P10809 1/20 0.64
GOT1 P17174 1/20 0.64
GLRA1 P23415 1/20 0.64
BLM P54132 1/20 0.64
HSPE1 P61604 1/20 0.64
TDP1 Q9NUW8 1/20 0.64
KDM4E B2RXH2 2/20 0.47
ALDH1A1 P00352 1/20 0.47
TP53 P04637 1/20 0.47
CYP3A4 P08684 1/20 0.47
MAPT P10636 1/20 0.47
HPGD P15428 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29358433 1.00 RARB (1.00) RARBRARGRARAMEN1KMT2A
SCHEMBL29397204 1.00 RARB (1.00) RARBRARGRARAMEN1KMT2A
SCHEMBL7689383 0.87 RARB (0.77) RARBRARGRARAMEN1KMT2A
Hydrochloric Acid SCHEMBL9738342 0.86 RARB (0.75) RARBRARGRARAMEN1KMT2A
SCHEMBL9944159 0.81 RARB (0.74) RARBRARGRARAMEN1KMT2A
SCHEMBL13980228 0.81 RARB (0.67) RARBRARGRARAMEN1KMT2A
SCHEMBL19639449 0.80 RARB (0.67) RARBRARGRARAMAPTSMN1; SMN2
SCHEMBL13980181 0.80 RARB (0.66) RARBRARGRARAMEN1KMT2A
SCHEMBL14566563 0.80 RARB (0.66) RARBRARGRARAMEN1KMT2A
SCHEMBL5827791 0.80 RARB (0.66) RARBRARGRARAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6248791-B1 Stimulating the differentiation of preadipocytic cells and therapies based thereon CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) 2001-06-19 US claimed
EP-0698392-B1 Compositions containing a RAR alpha specific ligand and at least one fatty acid CIRD GALDERMA (FR) 2000-11-29 EP claimed
US-20240390334-A1 COMPOSITIONS AND METHODS FOR MITIGATING ALCOHOL LIVER DISEASE RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) 2024-11-28 US disclosed
WO-2023044355-A1 COMPOSITIONS AND METHODS FOR MITIGATING ALCOHOL LIVER DISEASE CORNELL UNIVERSITY (US) 2023-03-23 WO disclosed
US-20220347163-A1 COMPOSITIONS AND METHODS FOR PROVIDING CARDIOPROTECTIVE EFFECTS CORNELL UNIVERSITY (US) 2022-11-03 US disclosed
US-20220304945-A1 METHODS OF TREATING METABOLIC SYNDROME RELATED CONDITIONS USING RETINOIC ACID RECEPTOR AGONISTS CORNELL UNIVERSITY (US) 2022-09-29 US disclosed
US-20220296579-A1 COMPOSITIONS AND METHODS FOR PROVIDING CARDIOPROTECTIVE EFFECTS CORNELL UNIVERSITY (US) 2022-09-22 US disclosed
CN-106211757-B Methods of treating metabolic syndrome-related conditions using retinoic acid receptor agonists 康奈尔大学 2022-06-07 CN disclosed
US-11207277-B2 Methods of treating diseases associated with high-fat diet and vitamin a deficiency using retinoic acid receptor agonists CORNELL UNIVERISITY (US) 2021-12-28 US disclosed
US-11191755-B2 Compositions and methods for providing cardioprotective effects CORNELL UNIVERSITY (US) 2021-12-07 US disclosed
US-11160769-B2 Methods of treating metabolic syndrome related conditions using retinoic acid receptor agonists CORNELL UNIVERSITY (US) 2021-11-02 US disclosed
US-20160039747-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use KING'S COLLEGE LONDON (GB) 2016-02-11 US disclosed
US-20150352070-A1 METHODS OF TREATING DISEASES ASSOCIATED WITH HIGH-FAT DIET AND VITAMIN A DEFICIENCY USING RETINOIC ACID RECEPTOR AGONISTS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-12-10 US disclosed
EP-2945701-A1 METHODS OF TREATING DISEASES ASSOCIATED WITH HIGH FAT DIET AND VITAMIN A DEFICIENCY USING RETINOIC ACID RECEPTOR AGONISTS Cornell University (US) 2015-11-25 EP disclosed
WO-2015138354-A1 COMBINATION THERAPY FOR HEAD AND NECK CANCER CORNELL UNIVERSITY (US) 2015-09-17 WO disclosed
WO-2015109231-A1 METHODS OF TREATING METABOLIC SYNDROME RELATED CONDITIONS USING RETINOIC ACID RECEPTOR AGONISTS CORNELL UNIVERSITY (US) 2015-07-23 WO disclosed
WO-2014113695-A1 METHODS OF TREATING DISEASES ASSOCIATED WITH HIGH FAT DIET AND VITAMIN A DEFICIENCY USING RETINOIC ACID RECEPTOR AGONISTS CORNELL UNIVERSITY (US) 2014-07-24 WO disclosed
CN-1121857-C RAR-gamma specific agonist ligands for increasing apoptosis rate GENTRE INTERNAT DE RECH S DERM (FR) 2003-09-24 CN disclosed
US-6248791-B1 Stimulating the differentiation of preadipocytic cells and therapies based thereon CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) 2001-06-19 US disclosed
CN-1203528-A RAR-gamma specific agonist ligands for increasing apoptosis rate GENTRE INTERNATIONAL DE RECH D (FR) 1998-12-30 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240390334-A1 COMPOSITIONS AND METHODS FOR MITIGATING ALCOHOL LIVER DISEASE NR1H3, NR1H2, RXRB RARB 8/4885RARG 10/4885RARA 9/4885
US-20220304945-A1 METHODS OF TREATING METABOLIC SYNDROME RELATED CONDITIONS USING RETINOIC ACID RECEPTOR AGONISTS RARA, RARG, RXRA RARB 4/4885RARG 2/4885RARA 1/4885
US-20220296579-A1 COMPOSITIONS AND METHODS FOR PROVIDING CARDIOPROTECTIVE EFFECTS RARB, RARG, RARA RARB 1/4885RARG 2/4885RARA 3/4885
US-11191755-B2 Compositions and methods for providing cardioprotective effects RARB, RARG, RARA RARB 1/4885RARG 2/4885RARA 3/4885
US-11160769-B2 Methods of treating metabolic syndrome related conditions using retinoic acid receptor agonists RARA, RARG, RXRA RARB 5/4885RARG 2/4885RARA 1/4885
US-20150352070-A1 METHODS OF TREATING DISEASES ASSOCIATED WITH HIGH-FAT DIET AND VITAMIN A DEFICIENCY USING RETINOIC ACID RECEPTOR AGONISTS RARA, RARB, RXRA RARB 2/4885RARG 5/4885RARA 1/4885
US-20220347163-A1 COMPOSITIONS AND METHODS FOR PROVIDING CARDIOPROTECTIVE EFFECTS RARB, RARG, RARA RARB 1/4885RARG 2/4885RARA 3/4885
US-20160039747-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use RARA, RARB, RARG RARB 2/4885RARG 3/4885RARA 1/4885
US-11207277-B2 Methods of treating diseases associated with high-fat diet and vitamin a deficiency using retinoic acid receptor agonists RARA, RXRA, RARG RARB 5/4885RARG 3/4885RARA 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.